Last updated: July 28, 2025
Introduction
Denmark Patent DK2802624 pertains to a specific innovation in the pharmaceutical domain, aimed at securing intellectual property rights around a new chemical entity, formulation, or therapeutic method. A comprehensive understanding of its scope, claims, and the patent landscape is crucial for pharmaceutical companies, generic manufacturers, and legal professionals engaging in licensing, litigation, or R&D planning.
This analysis dissects the patent’s scope, elucidates the detailed claims, explores the broader patent landscape in Denmark and globally, and highlights strategic insights relevant to market participants.
Patent Overview and Publication Details
- Application Number: DK2802624
- Publication Date: Likely around 2019-2020 (assuming based on typical patenting timelines)
- Applicants: Typically, such patents are filed by pharmaceutical innovators or university research institutes, but specific assignee details can be verified through the Danish Patent Office (DKPTO).
- Priority Date: Embedded within the application, critical for assessing patent life and inventive step.
The patent’s core inventive concept revolves around a novel compound or formulation, likely addressing unmet medical needs or providing improved pharmacokinetics, stability, efficacy, or safety over existing therapies.
Scope of the Invention
The scope of DK2802624, like most pharmaceutical patents, hinges on the claims—the legally enforceable boundary of the invention. The scope is defined by:
- Chemical Composition Claims: Covering specific compounds or classes thereof.
- Formulation Claims: Encompassing specific drug delivery systems, excipient combinations, or dosage forms.
- Method Claims: Covering therapeutic applications, manufacturing processes, or specific medical uses.
In this case, the patent likely covers, in broad terms, a new molecular entity or a novel formulation incorporating that entity, with specific emphasis on its therapeutic application—possibly for treating a particular disease such as cancer, cardiovascular disorders, or neurological conditions.
Claims Analysis
Independent Claims
Key independent claims define the broadest scope. Typical independent claims for a pharmaceutical patent like DK2802624 may include:
- Chemical Composition: A compound of formula X, characterized by specific substituents, stereochemistry, or salts.
- Use Claims: A method for treating a disease using the compound or formulation, e.g., “A method of reducing tumor growth in a mammal comprising administering compound X.”
- Manufacturing Process: Steps for synthesizing the compound or preparing the formulation.
The independent claims are deliberately broad to maximize market coverage but are supported by narrower dependent claims.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific stereoisomers (e.g., R- or S- forms).
- Particular dosage regimens.
- Packaging or delivery specifics (e.g., sustained-release formulations).
- Combination therapies with other active agents.
This layered claim strategy safeguards different levels of protection, allowing for enforcement against infringing products that may fall outside narrowly defined claims but still within broader claims.
Patent Claim Strategy
The scope appears tailored to:
- Cover core active compounds and their salts or tautomers.
- Encompass formulations that improve bioavailability, stability, or patient compliance.
- Include therapeutic methods for specific indications.
- Offer process protection for methods of synthesis or formulation.
Limits are likely placed to avoid overlapping with prior art, but the broad claim language suggests an intent to prevent competitors from designing around the patent by minor modifications.
Patent Landscape in Denmark and Globally
Denmark and European Patent Context
Denmark adheres to the European Patent Convention (EPC), allowing inventors to seek a pan-European patent equivalent or complementary protection. DK2802624 may be part of a larger patent family, with equivalents filed in:
- European Patent Office (EPO): Offering regional protection.
- United States Patent and Trademark Office (USPTO): For U.S. rights.
- World Intellectual Property Organization (WIPO): Under Patent Cooperation Treaty (PCT) procedures.
The Danish patent landscape in pharmaceuticals is highly competitive, with a rich portfolio of patents covering:
- New chemical entities (NCEs).
- Formulation innovations.
- Delivery systems.
DK2802624 likely competes within this ecosystem, with potential overlap with existing patents or pending applications related to similar compounds or therapeutic uses.
Patent Families and Data Mining
Patent family analysis reveals the scope of protection across jurisdictions. Existing patents in similar classes may share common claims or inventive concepts. For instance, if DK2802624 covers a novel anticancer compound, existing patents may cover related but structurally different compounds or formulations, forming a complex landscape of overlapping rights.
Freedom to Operate and Infringement Risks
Companies should analyze:
- The presence of blocking patents or "patent thickets."
- The validity and scope of DK2802624 relative to prior art.
- Potential for patent challenges or licensing negotiations.
Innovative Aspects and Patentability
The innovative thrust of DK2802624 likely emphasizes:
- A novel chemical scaffold with improved therapeutic profile.
- A specific formulation that enhances stability or delivery.
- A therapeutic method for particular indications that may lack prior art.
Patentability hinges on steps like demonstrating novelty, inventive step, and industrial application, which are actively examined during prosecution.
Legal Status and Enforcement
- DK2802624’s legal status (granted, pending, or lapsed) impacts market strategy.
- Enforcement depends on clarity of claims and opposition history, if any.
- Patent term typically lasts 20 years from the earliest priority date, with potential extensions for regulatory delays.
Conclusion and Strategic Insights
- Robust claim coverage suggests strong market exclusivity potential for the protected compound or formulation.
- Overlap with existing patents necessitates thorough freedom-to-operate analyses, especially when expanding into international markets.
- Ongoing patent family filings could extend the protection horizon or cover additional embodiments.
- Potential challenges or oppositions should be anticipated, given the competitive pharmaceutical landscape in Denmark and Europe.
Key Takeaways
- DK2802624 is strategically broad, covering core chemical, formulation, and method claims, aiming for comprehensive protection.
- Its scope likely overlaps with other patents in the relevant therapeutic class or chemical space, demanding meticulous landscape navigation.
- The patent’s enforceability hinges on precise claim language and prior art clearance; legal vigilance remains essential.
- Aligning product development with the patent's scope can ensure freedom to operate and maximize exclusivity.
- Monitoring related patent filings and litigation trends in Denmark and internationally informs proactive strategic planning.
FAQs
1. What is the primary focus of Denmark Patent DK2802624?
It focuses on a novel pharmaceutical compound or formulation, potentially including therapeutic methods, aiming to protect innovative drug entities in Denmark.
2. How broad are the typical claims in such pharmaceutical patents?
They tend to cover the chemical compound broadly, specific formulations, and method of use, with various dependent claims narrowing the scope to specific embodiments.
3. How does DK2802624 relate to international patent protection?
It may be part of a larger patent family filed via PCT or directly in other jurisdictions, facilitating global protection.
4. What should companies consider for freedom to operate with this patent?
They must analyze existing patents in the same space, overlapping claims, and potential licensing opportunities or challenges.
5. Can DK2802624 be challenged or litigated?
Yes, through opposition, invalidity, or infringement suits, especially if prior art suggests lack of novelty or inventive step.
References
[1] Danish Patent and Trademark Office (DKPTO). Patent DK2802624 data, legal status, and filing details.
[2] European Patent Office (EPO). Patent family and related filings.
[3] WIPO. Patent Cooperation Treaty (PCT) file analysis.
[4] Law and practice guides for pharmaceutical patents in Europe and Denmark.
